Monitor the stock price relative to conversion price and floor price; if stockholder approval is not obtained, conversion could trigger massive dilution. The mandatory repayment from future financings suggests the company may need to raise more capital, compounding dilution. The existing ELOC with White Lion Capital and the new note create a complex capital structure with multiple layers of senior secured debt.
Price Chart
Executive Summary
Glucotrack entered into a securities purchase agreement to issue a senior secured convertible promissory note with a 22% original issue discount, 8% interest, and 9-month maturity, along with warrants to purchase common stock at $1.5975 per share. The note is secured by substantially all assets and ranks senior to future debt. Proceeds will fund working capital and repay liabilities. The combination of heavy dilution (200% warrant coverage), a low conversion price (80% of VWAP), and mandatory repayment provisions from future financings creates a highly dilutive and potentially distressed financing structure.
Key Facts
- Senior secured convertible promissory note with 22% OID, 8% interest, 9-month maturity
- Warrants to purchase 200% of principal amount divided by $0.6390, exercise price $1.5975, 5-year term
- Conversion price = lower of Nasdaq minimum price or 80% of 15-day VWAP, floor = 20% of Nasdaq minimum price
- Mandatory repayment from 100% of asset sales, debt/equity issuances, ELOC proceeds applied to note
- Stockholder approval required for issuance beyond 19.99% cap; failure triggers penalty shares and additional meetings
- Placement agent fee: 7% cash fee, 4% warrant coverage, $50k expense cap
- Existing security agreement with White Lion Capital, pari passu with new note
- 2,368,237 shares outstanding as of date; dilution from conversion/warrants could be massive relative to base
Financial Impact
Undisclosed principal amount; note includes 22% OID; warrants 200% of principal at $0.6390 reference; conversion price at 80% of 15-day VWAP; floor at 20% of Nasdaq minimum price
Risk Factors
- Massive dilution from conversion and warrants relative to tiny base of 2.4M shares outstanding
- Potential for forced repayment from future financings limits flexibility
- Low floor price (20% of Nasdaq minimum) could lead to extreme dilution if stock declines
- Stockholder approval failure triggers penalty shares and additional meetings
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-048139 |
| Exhibit: ex10-2.htm | 0001493152-26-048139 |
| Exhibit: ex4-1.htm | 0001493152-26-048139 |
| Exhibit: ex4-2.htm | 0001493152-26-048139 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.4032 | awaiting T+60 | — | $1.61 (−299.31%) |
Oct 19, 2026 7d ago | 8-K | $0.6511 | awaiting T+60 | — | $1.61 (+147.27%) |
Oct 13, 2026 13d ago | S-1/A | $0.8873 | awaiting T+60 | — | $1.61 (−81.45%) |
Oct 13, 2026 13d ago | 425 | $0.8873 | awaiting T+60 | — | $1.61 (+81.45%) |
Sep 28, 2026 28d ago | 8-K | $1.74 | awaiting T+60 | — | $1.61 (−7.47%) |
Sep 24, 2026 4w ago | 424B5 | $1.82 | awaiting T+60 | — | $1.61 (+11.54%) |
Sep 24, 2026 4w ago | 8-K | $1.82 | awaiting T+60 | — | $1.61 (+11.54%) |
Sep 23, 2026 4w ago | 425 | $2.03 | awaiting T+60 | — | $1.61 (−20.69%) |
Sep 23, 2026 4w ago | 8-K | $2.03 | awaiting T+60 | — | $1.61 (−20.69%) |
Sep 18, 2026 5w ago | 8-K | $2.30 | awaiting T+60 | — | $1.61 (−30.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers